

## Erratum

# Erratum to “The allosteric interaction of otenzepad (AF-DX 116) at muscarinic M<sub>2</sub> receptors in guinea pig atria” [Eur. J. Pharmacol. 416 (2001) 235–244]<sup>☆</sup>

Alfred Lanzafame, Arthur Christopoulos, Fred Mitchelson<sup>\*</sup>

*Department of Pharmaceutical Biology and Pharmacology, Victorian College of Pharmacy (Monash University),  
381 Royal Parade, Parkville, Victoria 3052, Australia*

The publisher regrets that in the above-mentioned article, errors were printed in Table 3.  
Herewith is the correct Table 3.

<sup>☆</sup> PII of original article S0014-2999(01)00827-5

<sup>\*</sup> Corresponding author. Tel.: +61-3-9903-9562; fax: +61-3-9903-9638.

E-mail address: fjmite@unimelb.edu.au (F. Mitchelson).

Table 3

Concentration ratios produced by the combination of the two inhibitors, otenzepad and *N*-methylscopolamine using carbachol as agonist

First inhibitor ( $\mu\text{M}$ )	$\text{CR}_1^a$	Second inhibitor ( $\mu\text{M}$ )	$\text{CR}_2^b$	Experimental combination $\text{CR}^c$				Predicted combination $\text{CR}^d$	
				$\text{CR}_{40}$	$\text{CR}_{120}$	$\text{CR}_{180}$	$\text{CR}_{240}$	Two competitive	Allosteric + competitive
Otenzepad (10)	223 (185–269; 5)	NMS (0.01)	186 (83–415; 4)	447 (334–598; 5)	609 (301–1229; 4)	543 <sup>e</sup> (408–723; 3)	544 <sup>e</sup> (376–776; 3)	409 (369–453; 5)	456 (378–550; 5)
NMS (0.01)	186 (83–415; 4)	Otenzepad (10)	266 (219–324; 17)	674 (371–1101; 4)	–	767 <sup>e</sup> (535–1101; 4)	781 <sup>e</sup> (539–1133; 4)	461 (332–640; 4)	558 (371–839; 4)
NMS (0.03)	248 (221–277; 4)	Otenzepad (10)	266 (219–324; 17)	636 <sup>e</sup> (518–782; 4)	900 <sup>e,f</sup> (782–1036; 4)	–	–	513 (486–541; 4)	638 (598–681; 4)

Concentration ratio is represented by CR and *N*-methylscopolamine is represented by NMS.<sup>a</sup>Geometric mean CR for first inhibitor (95% confidence limits; number of experiments).<sup>b</sup>Determined in separate experiments where the second inhibitor was used alone.<sup>c</sup> $\text{CR}_{40-240}$ : subscript represents equilibration time (min) with the combination of inhibitors.<sup>d</sup>Two competitive: predicted CR for combination of two competitive inhibitors, allosteric + competitive: predicted CR for combination of an allosteric modulator with a competitive antagonist, given by Eq. (2) (Section 2) using the  $\alpha'$  value of 522 for the interaction between otenzepad and *N*-methylscopolamine.<sup>e</sup>Significantly different ( $P < 0.05$ ) from CR predicted for the combination of two competitive antagonists.<sup>f</sup>Significantly different ( $P < 0.05$ ) from CR predicted for the combination of an allosteric modulator and a competitive antagonist.